Clinical Trial Update: Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating neoadjuvant docetaxel with or without selumetinib in patients with triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Selumetinib (selumetinib)

Snippet

Sponsor: Russian Academy of Medical Sciences | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN